NIKKEI 225
38,617.10 -329.83 (-0.85%) HANG SENG
19,195.60 -25.02 (-0.13%) CRUDE OIL
77.59 -1.07 (-1.36%) GOLD FUTURES
2,389.00 -36.90 (-1.52%) DOW
39,618.37 -254.62 (-0.64%) Bitcoin GBP
54,573.57 -153.95 (-0.28%)
NVO Sep 2024 75.000 put
- Benzinga
Australia Bans Replica Versions Of Popular Weight-Loss Drugs From Novo Nordisk, Eli Lilly On Safety Concerns
Australia announced on Wednesday that it would ban compounded versions of weight-loss drugs like Novo Nordisk A/S’s (NYSE:NVO) Ozempic and Eli Lilly And Co’s (NYSE:LLY) Mounjaro, citing safety concerns. Recently, the Chinese regulatory authority approved Eli Lilly’s diabetes drug, tirzepatide. Health Minister Mark Butler emphasized that these unregulated copies have not undergone rigorous testing, leading to potential patient risks. Related: The Ozempic Diet: Nestle Launches $5 Pizza For Weight
- Zacks
Play These New ETFs to Tap Lucrative Weight Loss Drug Market
Global obesity rates have nearly tripled since 1975, per WHO and Goldman Sachs. The growing usage of GLP-1 drugs in weight management now makes the industry a thriving one.
- Reuters
Eli Lilly's diabetes drug tirzepatide gets approval in China
SHANGHAI (Reuters) -Eli Lilly said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk in the key Asian market. Novo Nordisk's popular diabetes drug Ozempic won approval from China in 2021 and the company saw sales of the weekly injection in the greater China region that includes Hong Kong and Taiwan double to 4.8 billion Danish Krone ($698 million) last year. Eli Lilly did not say when sales would begin in China or how many doses would be supplied.
